Compare iShares MSCI France ETF (EWQ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Tango Therapeutics Inc. — how do they compare? iShares MSCI France ETF trades at $41.52 (market cap $330.41M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 11.3× iShares MSCI France ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 57 Days and Tango Therapeutics Inc. for 0 Days on average.
| EWQ | TNGX | |
|---|---|---|
Market Cap | $330.41M | $3.75B |
Volume | 244,426 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $32.90 |
52-Week Low | $41.24 | $7.50 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is trading at $41.63, up 0.95% with a bearish technical signal from moving averages. The stock faces European market pressures including ECB rate hikes and energy-driven inflation concerns. Key support sits at $41 with resistance at $42, while RSI indicators show mixed signals between neutral and oversold conditions.
European economic uncertainty and monetary tightening create headwinds, though Goldman Sachs notes resilience in European equities. The stock's technical weakness suggests cautious near-term positioning amid macroeconomic volatility in eurozone markets.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
